Efferocytosis‐Driven Reduction of Neuroinflammation and Amyloid Beta Burden via Novel GAS6 Fusion Protein, GAIA: A Promising Therapeutic Approach in Alzheimer's Disease
GAIA-Aβ effectively reduces Aβ burden while mitigating neuroinflammation, presenting a favorable safety profile compared to existing anti-Aβ antibodies. These findings highlight the potential of GAIA-Aβ as an improved therapeutic approach for Alzheimer's disease, addressing the limitations of current anti-Aβ immunotherapies.
Authors
- Heeju Han
- Seong Beom An
- Juho Lee (ORCID: https://orcid.org/0009-0007-1756-9825)
- Sung Wook Kim (ORCID: https://orcid.org/0000-0001-9572-4762)
- Jin Kyung Lee
- Sanghoon Park
- Bokyung Kim
- Eun Jung Lee
- Jaemin Shin
- Gyunam Jang
Institutions
- Hanlim Pharm (South Korea) (KR)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_101799
- Primary Topic
- Phagocytosis and Immune Regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00